Key result
Third-generation progestogens linked to higher venous thrombosis risk vs second-generation via protein C resistance.
Why the study?
Do third-generation progestogens increase the risk of venous thrombosis compared to second-generation progestogens in women using oral contraceptives?
Do third-generation progestogens increase the risk of venous thrombosis compared to second-generation progestogens in women using oral contraceptives?
The debate continues regarding the increased venous thrombosis risk with third-generation versus second-generation oral contraceptives, though acquired APC resistance has emerged as a potential biological mechanism.
No takes yet. Share an insight, caveat, or question.
May warrant preferring second-generation progestogens in high-risk women; leaves open confirmation of APC resistance mechanism in prospective studies.
Margaret Thorogood (1998) conducted a review in Venous thrombosis. Third-generation progestogens vs. Second-generation progestogens was evaluated on Venous thrombosis. Third-generation progestogens are debated to have a higher risk of venous thrombosis compared to second-generation preparations, potentially due to higher acquired activated protein C resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: